Literature DB >> 27631193

SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.

Eleni Aklillu1, Abiy Habtewold1,2, Eliford Ngaimisi1,3, Getnet Yimer1,2, Sabina Mugusi4, Wondwossen Amogne5, Tasmin Reuter6, Andreas Meid6, Michael Marcus Hoffmann7, Johanna Weiss6.   

Abstract

The solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene encodes for a membrane-bound organic anion transporter protein involved in active cellular influx of many endogenous compounds and xenobiotics. SLCO1B1 genetic variation is associated, for example, with highly variable rifampicin exposure, thus influencing the cornerstone antituberculosis therapy, especially in sub-Saharan Africa where it is a key therapeutic modality. Yet, there is no SLCO1B1-guided pharmacogenetic dosing recommendation for rifampicin to reduce the risk of adverse events or therapy failure. Accordingly, comparative characterization of SLCO1B1, particularly within understudied African populations, is crucial and timely for global precision medicine, given the importance of antituberculosis therapy worldwide. Therefore, we report here the allele, genotype, and haplotype frequencies for common SLCO1B1 gene polymorphisms among Europeans (N = 57), Tanzanians (N = 361), and Ethiopians (N = 632). Our results show that the allele frequencies of rs4149032T, rs2306283G, rs11045819A, and rs4149056C differ significantly among Ethiopians (48.1%, 60.3%, 2.8%, 19.1%). Tanzanians (51.9%, 86.8%, 4.7%, 3.2%), and Europeans (19.8%, 34.2%, 7.9%, 22.8%) (p < 0.001). Notably, the most common haplotypes in Tanzanians (TGCT; g.38664T + c.388G + c.463C + c.521T = 61.1%) and Europeans (CGCT, all wild-type SLCO1B*1A = 59.8%) occurred at a much lower frequency in Ethiopians (TGCT = 38.8% and CGCT = 31.6%) (p < 0.0001). Additionally, the nonfunctional SLCO1B1 haplotypes CGCC (*15) and CACC (*5) are relatively common or detectable in Ethiopians (14.1%, 3.2%, respectively) and Europeans (18.1%, 2.8%) but rare in Tanzanians (1.9% and 0%, respectively) (p < 0.001). These new observations collectively underscore that precision medicine for rifampicin and other cornerstone therapeutics will require a comparative study of each and every population in the African continent as well as globally. SLCO1B1 and its extensive within- and between-population variations have to be carefully borne in mind for global precision medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27631193     DOI: 10.1089/omi.2016.0119

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  11 in total

1.  Conference report: pharmacogenomics in special populations at WCP2018.

Authors:  Guilherme Suarez-Kurtz; Eleni Aklillu; Yoshiro Saito; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2019-01-24       Impact factor: 4.335

2.  Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Authors:  Zelalem Petros; Ming Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  OMICS       Date:  2017-04

Review 3.  Genetic Diversity in Drug Transporters: Impact in African Populations.

Authors:  Iris Rajman; Laura Knapp; Imad Hanna
Journal:  Clin Transl Sci       Date:  2020-03-31       Impact factor: 4.689

4.  Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Authors:  Eliford Ngaimisi Kitabi; Omary Mashiku Sylivester Minzi; Sabina Mugusi; Philip Sasi; Mohamed Janabi; Ferdinand Mugusi; Leif Bertilsson; Jürgen Burhenne; Eleni Aklillu
Journal:  Sci Rep       Date:  2018-11-05       Impact factor: 4.379

5.  Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Authors:  Ritah F Mutagonda; Appolinary A R Kamuhabwa; Omary M S Minzi; Siriel N Massawe; Muhammad Asghar; Manijeh V Homann; Anna Färnert; Eleni Aklillu
Journal:  Malar J       Date:  2017-07-03       Impact factor: 2.979

6.  N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Natasa Djordjevic
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

7.  Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Authors:  Worku Bedada; Fernando de Andrés; Ephrem Engidawork; Jemal Hussein; Adrián LLerena; Eleni Aklillu
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

Review 8.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12

9.  Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population.

Authors:  Abshir A Ali; Mikko Aalto; Jon Jonasson; Abdimajid Osman
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

10.  Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.

Authors:  Sabina Mugusi; Abiy Habtewold; Eliford Ngaimisi; Wondwossen Amogne; Getnet Yimer; Omary Minzi; Eyasu Makonnen; Christopher Sudfeld; Jürgen Burhenne; Eleni Aklillu
Journal:  Front Pharmacol       Date:  2020-02-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.